Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-89
SponsorUniversity of Alabama at Birmingham
About this trial
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
Eligibility criteria
Qualifiers
Patients 18-89 years of age
admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA
eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well)
Disqualifiers
diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%)
prescribed anticoagulation prior to stroke
treated with intravenous thrombolysis
treated with mechanical thrombectomy
Trial design
Treatments tested in this trial
- CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov